Related Experiment Video
Updated: May 26, 2026
12:58
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
A novel agent effective against Clostridium difficile infection.
Sofya Dvoskin1, Wei-Chu Xu, Neal C Brown
1GLSynthesis, Inc Worcester, Massachusetts, USA.
Antimicrobial Agents and Chemotherapy
|December 29, 2011
Summary
A new synthetic purine, N(2)-(3,4-Dichlorobenzyl)-7-(2-[1-morpholinyl]ethyl)guanine (MorE-DCBG, 362E), effectively inhibits Clostridium difficile growth and shows promise for treating colitis.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Clostridium difficile is a significant cause of antibiotic-associated diarrhea and colitis.
- Current treatments for severe C. difficile infections, such as vancomycin, face challenges with resistance and recurrence.
- Novel therapeutic agents targeting specific C. difficile pathways are needed.
Purpose of the Study:
- To evaluate the efficacy of a novel synthetic purine, N(2)-(3,4-Dichlorobenzyl)-7-(2-[1-morpholinyl]ethyl)guanine (MorE-DCBG, 362E), as a potential treatment for Clostridium difficile infections.
- To assess the in vitro and in vivo activity of MorE-DCBG against C. difficile.
Main Methods:
- Synthesized N(2)-(3,4-Dichlorobenzyl)-7-(2-[1-morpholinyl]ethyl)guanine (MorE-DCBG, 362E).
- Tested the in vitro inhibitory activity of MorE-DCBG against various C. difficile strains.
- Evaluated the efficacy of orally administered 362E in a hamster model of C. difficile-specific colitis.
Main Results:
- MorE-DCBG and its analogs demonstrated potent inhibition of C. difficile growth in vitro.
- 362E effectively inhibited a broad spectrum of C. difficile strains.
- Oral administration of 362E in hamsters was comparable in efficacy to oral vancomycin for treating C. difficile colitis.
Conclusions:
- N(2)-(3,4-Dichlorobenzyl)-7-(2-[1-morpholinyl]ethyl)guanine (MorE-DCBG, 362E) is a potent inhibitor of Clostridium difficile replication.
- 362E represents a promising therapeutic candidate for C. difficile infections, including colitis.
- Further investigation into 362E as a potential alternative to vancomycin is warranted.
Related Concept Videos
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
01:27Chemical Agents for Microbial Control
Chemicals play important roles in controlling microbial growth by targeting microbial structures and functions as sanitizers, antiseptics, disinfectants, and sterilants.Alcohols are commonly used sanitizers, effectively disrupting lipid membranes, which compromises cell integrity. They are also used as antiseptics and disinfectants due to their rapid action and versatility.Phenols and their derivatives phenolics , known for denaturing proteins and disrupting cell membranes, are particularly...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:28Antimicrobial Effectiveness
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...